Vir Biotechnology, Inc.

VIR

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Baker Bros. Advisors OrbiMed Advisors

AI Signal

## Baker Bros.

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 542,539Value: $3.3M

## Baker Bros. Initiates Large New Position in Vir Biotechnology (VIR) Baker Brothers, the largest biotech-specialist fund known for extremely concentrated, high-conviction bets, initiated a new position of 542,539 shares in VIR worth ~$3.27B — a significant commitment signaling strong confidence in the company's pipeline. Vir's lead programs center on its chronic hepatitis B (HBV) functional cure efforts, particularly tobeberane (VIR-2218, an RNA interference agent) in combination with other modalities, with pivotal-stage data readouts expected to be key near-term catalysts. Given Baker Bros.' track record of building positions ahead of major clinical inflections in infectious disease and liver targets, this filing suggests the fund sees underappreciated probability of clinical success in HBV, an indication with massive unmet need and no current functional cure.

OrbiMed AdvisorsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

AAVXF2 funds ALMS2 funds ARGX2 funds IRON2 funds BCRX2 funds CTMX2 funds PRAX2 funds DYN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: OrbiMed Initiates $14.4M Position in VIR** OrbiMed's new stake suggests confidence in VIR's pipeline momentum, likely centered on VIR-2482 (monoclonal antibody for RSV in older adults), which reported positive Phase 2 data in 2023 and is advancing toward Phase 3. The timing aligns with anticipated near-term catalysts including potential Phase 3 initiation and regulatory feedback on the RSV program, a high-value indication given seasonal epidemiology and aging demographics.